|
|
 |
SODIUM STARCH GLYCOLATE TYPE A Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SORBITAN SESQUIOLEATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SORBITAN MONOOLEATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SORBITAN MONOLAURATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM CITRATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM PHOSPHATE, DIBASIC, ANHYDROUS Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM ACETATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM BORATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM STEARYL FUMARATE Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|
 |
SODIUM PHOSPHATE, MONOBASIC, ANHYDROUS Drug Excipient Business Development Opportunity Report, 2024 |
$399.00 |
|
$399.00 |
|
|